MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

BioMarin Pharmaceutical Inc

Geschlossen

BrancheGesundheitswesen

57.3 -1.9

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

56.95

Max

58.51

Schlüsselkennzahlen

By Trading Economics

Einkommen

61M

186M

Verkäufe

-2.2M

745M

KGV

Branchendurchschnitt

21.567

39.857

Gewinnspanne

24.919

Angestellte

3,040

EBITDA

28M

224M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+64.09% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.1B

11B

Vorheriger Eröffnungskurs

59.2

Vorheriger Schlusskurs

57.3

Nachrichtenstimmung

By Acuity

54%

46%

306 / 376 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Aug. 2024, 11:30 UTC

Top News

S&P 500 Futures Up In Premarket Trading; Target, Keysight Technologies Lead

Peer-Vergleich

Kursveränderung

BioMarin Pharmaceutical Inc Prognose

Kursziel

By TipRanks

64.09% Vorteil

12-Monats-Prognose

Durchschnitt 95.78 USD  64.09%

Hoch 120 USD

Tief 70 USD

Basierend auf 21 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für BioMarin Pharmaceutical Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

21 ratings

16

Buy

5

Halten

0

Sell

Technischer Score

By Trading Central

59.405 / 62.19Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Very Strong Bearish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

306 / 376 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.